SunPillar is the first Synthetic Biology Company, founded in 1997.
Our mission is to
translate biological constructs into viable human therapeutics.
SunPillar has the first issued
patents to riboregulators (U.S. Patent Issued 2001, No. 6,323,00) and owns multiple patents
US, Canada and Europe.
Our foundational technology, Nucline 5-3, is the first patented ribonucleic
drug and is
capable of delivering a genetic message to a cell based on the genes the cell expresses.
Nucline is a nanomolecular cellular robot capable of executing specific instructions to reprogram or even kill a cell.
SunPillar is involved in development of anti-cancer & antiviral therapeutics, nanosensors, and licensing.
is a privately owned company.
Translating agene or gene profile into a drug can require
years of development and hundreds of millions in R&D costs.
SunPillar's exclusive technology allows a company
to bypass this arduous and expensive step. Nucline lets a company put their own gene or gene profile into the drug for detection.
If the genes are present, then Nucline is activated to produce a gene of the researcher's choice.
Nucline can be synthesized
in 24-48 hours, so the drug is ready in days not years.